Osimertinib for patients with EGFR T790M mutation-positive non –small-cell lung cancer and a poor performance status

ConclusionsOsimertinib therapy demonstrates promising efficacy and acceptable safety in patients withEGFR T790M mutation-positive NSCLC who have poor PS.

Source: Japanese Journal of Clinical Oncology - March 28, 2019 Category: Cancer & Oncology Source Type: research